ZSAN Zosano Pharma

$-0.02 (-3.85%)

ZSAN Stock Analysis Overview

What this means: InvestorsObserver gives Zosano Pharma (ZSAN) an overall rank of 32, which is below average. Zosano Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 32 means that 68% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Zosano Pharma (ZSAN) Analyst Forecast

Next 12 months ➝MEAN$3.83+818.30%HIGH$7.00+1577.05%LOW$2.00+379.16%Current Price$0.4252-week High$2.4552-week Low$0.41
  • Last Price$0.42
  • Previous Close$0.43
  • Change $-0.02
  • Open$0.43
  • Volume2,346,554
  • Avg. Volume (100-day)4,961,617
  • Market Capitalization$40M
  • Days Range $0.41 - $0.43
  • 52-week Range $0.41 - $2.45
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-1.38
  • Earnings Date11/12/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta-0.707
  • PEG Ratio
Zosano Pharma Corp is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications. The company only operating segment being developing human pharmaceutical products. All the business activities of the firm is functioned through the market of the United States. Its product includes Qtrypta (M207) which is a formulation of zolmitriptan delivered utilizing an Adhesive Dermally-Applied Microarray technology.